{"content":"<li class=\"n-box-item date-title\" data-end=\"1545195599\" data-start=\"1545109200\" data-txt=\"Monday, December 23, 2019\">Tuesday, December 18, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3418052\" data-ts=\"1545173317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSAT\" target=\"_blank\">GSAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418052-globalstar-raising-capital-shares-down-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globalstar raising capital; shares down 10%</a></h4><ul><li>The company is attempting to raise $60M in an equity offering, with underwriter greenshoe for up to another $9M of common stock.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17361969-globalstar-inc-announces-proposed-public-offering-60-million-shares-voting-common-stock\" target=\"_blank\">Press Release</a></li><li><a href='https://seekingalpha.com/symbol/GSAT' title='Globalstar, Inc.'>GSAT</a> <font color=\"red\">-9.7%</font> after hours to $0.32.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418052\" data-linked=\"Globalstar raising capital; shares down 10%\" data-tweet=\"$GSAT - Globalstar raising capital; shares down 10% https://seekingalpha.com/news/3418052-globalstar-raising-capital-shares-down-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3418052-globalstar-raising-capital-shares-down-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418050\" data-ts=\"1545172652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADRO\" target=\"_blank\">ADRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418050-mu-fdx-jbl-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MU, FDX &amp; JBL among notable after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a> <font color=\"green\">+25.9%</font>. <a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a> <font color=\"green\">+10.3%</font>. <a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color=\"green\">+3.3%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology'>SURF</a> <font color=\"red\">-19.1%</font>. <a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color=\"red\">-7.0%</font>. <a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a> <font color=\"red\">-5.9%</font>. <a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy Inc'>CHAP</a> <font color=\"red\">-4.8%</font>. <a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color=\"red\">-3.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418050\" data-linked=\"MU, FDX &amp; JBL among notable after hour movers\" data-tweet=\"$ADRO $ADRO $JBL - MU, FDX &amp; JBL among notable after hour movers https://seekingalpha.com/news/3418050-mu-fdx-jbl-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418050-mu-fdx-jbl-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418038\" data-ts=\"1545170173\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAGE\" target=\"_blank\">SAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418038-sage-therapeutics-files-for-mixed-shelf-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sage Therapeutics files for mixed shelf offering</a></h4><ul><li>Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1597553/000119312518352130/d674515ds3asr.htm\" target=\"_blank\">prospectus </a>for an unspecified mixed shelf offering.</li><li>Shares are up <font color=\"green\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418038\" data-linked=\"Sage Therapeutics files for mixed shelf offering\" data-tweet=\"$SAGE - Sage Therapeutics files for mixed shelf offering https://seekingalpha.com/news/3418038-sage-therapeutics-files-for-mixed-shelf-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3418038-sage-therapeutics-files-for-mixed-shelf-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418030\" data-ts=\"1545169332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SURF\" target=\"_blank\">SURF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418030-surface-oncology-shuffles-pipeline-cash-runway-extended-shares-down-16-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Surface Oncology shuffles pipeline; cash runway extended; shares down 16% after hours</a></h4><ul><li>Prompted by a potential safety signal in a Phase 1 trial and a crowded field in CD47 inhibitors, Surface Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology'>SURF</a>) will significantly <a href=\"https://seekingalpha.com/pr/17361972-surface-oncology-resets-portfolio-priorities-extends-cash-runway-2021\" target=\"_blank\">reduce its investment</a> in candidate SRF231 while it identifies a better dosing regimen. It plans to release additional data in H2 2019.</li><li>The company will now deploy resources to advance two preclinical programs, SRF617 and SRF388, into the clinic. It expects to file an IND for the latter by late 2019. The Phase 1 study of NZV930, in collaboration with Novartis, will continue. Its CD39 and IL-27 programs will remain priorities as well.</li><li>The changes should extend its cash runway through 2021.</li><li>Shares are down <font color=\"red\">16%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418030\" data-linked=\"Surface Oncology shuffles pipeline; cash runway extended; shares down 16% after hours\" data-tweet=\"$SURF - Surface Oncology shuffles pipeline; cash runway extended; shares down 16% after hours https://seekingalpha.com/news/3418030-surface-oncology-shuffles-pipeline-cash-runway-extended-shares-down-16-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3418030-surface-oncology-shuffles-pipeline-cash-runway-extended-shares-down-16-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418024\" data-ts=\"1545168772\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418024-jabilplus-10-on-q1-beats-upside-revenue-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil +10% on Q1 beats, upside revenue guide</a></h4><ul><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) <font color=\"green\">gains 10.3%</font> after Q1 beats with 17% Y/Y revenue growth. Q2 guidance has upside revenue from $5.8B to $6.4B (consensus: $5.84B) and in-line EPS from $0.51 to $0.71 (consensus: $0.61).</li><li>Earnings call is scheduled for 4:30 PM ET with a webcast available <a href=\"https://investors.jabil.com/\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17361993-jabil-posts-record-first-quarter-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417996-jabil-beats-0_02-beats-revenue\" target=\"_blank\">Jabil beats by $0.02, beats on revenue</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418024\" data-linked=\"Jabil +10% on Q1 beats, upside revenue guide\" data-tweet=\"$JBL - Jabil +10% on Q1 beats, upside revenue guide https://seekingalpha.com/news/3418024-jabilplus-10-on-q1-beats-upside-revenue-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3418024-jabilplus-10-on-q1-beats-upside-revenue-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418021\" data-ts=\"1545168475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADRO\" target=\"_blank\">ADRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418021-aduro-bio-out-licenses-cgas-sting-inhibitor-program-to-eli-lilly-shares-up-32-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aduro Bio out-licenses cGAS-STING inhibitor program to Eli Lilly; shares up 32% after hours</a></h4><ul><li>Aduro Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a>) is up <font color=\"green\">32%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17362018-lilly-aduro-biotech-announce-research-collaboration-license-agreement-develop-novel\" target=\"_blank\">licensing deal</a> with Eli Lilly (NYSE:<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a>) for its cGAS-STING Pathway Inhibitor program for the potential treatment of autoimmune and inflammatory disorders.</li><li>Under the terms of the agreement, Aduro will receive $12M upfront, up to $620M in milestones per product and single-to-low-double-digit royalties on net sales. Aduro will also receive research funding and has the option to co-fund development of each product in exchange for higher royalties.</li><li>STING-related ticker: (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3408159-investors-underwhelmed-aduros-early-stage-data-sting-candidate-shares-11-percent\" target=\"_blank\">Investors underwhelmed with Aduro's early-stage data on STING candidate; shares down 11%</a> (Nov. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418021\" data-linked=\"Aduro Bio out-licenses cGAS-STING inhibitor program to Eli Lilly; shares up 32% after hours\" data-tweet=\"$ADRO $ADRO $LLY - Aduro Bio out-licenses cGAS-STING inhibitor program to Eli Lilly; shares up 32% after hours https://seekingalpha.com/news/3418021-aduro-bio-out-licenses-cgas-sting-inhibitor-program-to-eli-lilly-shares-up-32-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3418021-aduro-bio-out-licenses-cgas-sting-inhibitor-program-to-eli-lilly-shares-up-32-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418017\" data-ts=\"1545168102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LRCX\" target=\"_blank\">LRCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418017-micronminus-7-on-mixed-q1-downside-guide-capex-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron -7% on mixed Q1, downside guide, capex cut</a></h4><ul><li><strong>Guidance update:</strong> Micron guides Q2 revenue of $5.7B to $6.3B (consensus: $7.18B) and EPS of $1.65 to $1.85 (consensus: $2.45) with NAND and DRAM ships both expected weaker. FY19 capex guided from $9.0B to $9.5B, reduced by $1.25B from the prior guidance.</li><li><strong>Conference call update: </strong>Micron reiterates that SSD will be in a year of transition with share gains expected to resume in 2020.</li><li>DRAM demand weakened in Q1 with limited near-term visibility. The company thinks some customers carried higher than normal inventory levels and now customers are bringing down the level. Smartphone demand continues to weaken and Micron is seeing the impact of CPU shortages.</li><li>DRAM bit growth is expected to grow Q/Q going into Q3. Micron lowers its FY19 bit growth guidance to 15% from 20% and plans to significantly reduce capex in the period.</li><li>NAND bit growth expected at 35% with supply growth exceeding demand in FY19. Company lowers its NAND bit growth estimate and capex for FY19 but expects demand to accelerate in 2H19.</li><li>Lam Research (NASDAQ:<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a>) and Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) are down <font color=\"red\">2.8%</font> and <font color=\"red\">1.9%</font>, respectively, after Micron's capex cuts.</li><li>Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) reports Q1 results that beat on EPS but missed on revenue despite a 16% Y/Y revenue growth. Guidance will come on the earnings call scheduled for 4:30 PM ET with a webcast available <a href=\"http://investors.micron.com/\" target=\"_blank\">here</a>.</li><li>Will update post with information from the call and presentation.</li><li><a href=\"https://seekingalpha.com/pr/17361973-micron-technology-inc-reports-results-first-quarter-fiscal-2019\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417991-micron-technology-beats-0_02-misses-revenue\" target=\"_blank\">Micron Technology beats by $0.02, misses on revenue</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418017\" data-linked=\"Micron -7% on mixed Q1, downside guide, capex cut\" data-tweet=\"$LRCX $LRCX $AMAT - Micron -7% on mixed Q1, downside guide, capex cut https://seekingalpha.com/news/3418017-micronminus-7-on-mixed-q1-downside-guide-capex-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3418017-micronminus-7-on-mixed-q1-downside-guide-capex-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>323&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418011\" data-ts=\"1545167985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418011-fedex-off-nearly-5-after-cutting-guidance-ups-dips-alongside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx off nearly 5% after cutting guidance; UPS dips alongside</a></h4><ul><li>Full-year fiscal 2019 EPS is now seen at $12.65-$13.40 vs. $15.85-$16.45 previously. EPS excluding charges is now guided to $15.50-$16.60 vs. $17.20-$17.80 earlier.</li><li>At issue is further weakening in international economic conditions and a delay in the realization of benefits from the TNT Express acquisition - operating income boost of $1.2B-$1.5B won't be achieved until fiscal 2020.</li><li>CFO Alan Graf: \"Global trade has slowed in recent months and leading indicators point to ongoing deceleration in global trade near-term.\"</li><li>The company is putting in place cost-cutting measures such as a voluntary buyout program for some workers, international network capacity reductions, limited hiring in staff functions, and reductions in discretionary spending.</li><li>A <a href=\"http://investors.fedex.com\" target=\"_blank\">conference call</a> is set for 5:30 ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417993-fedex-beats-0_09-beats-revenue\" target=\"_blank\">FedEx beats by $0.09, beats on revenue</a> (Dec. 18)</li><li><a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a> <font color=\"red\">-4.75%</font> after hours, <a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a> <font color=\"red\">-2.35%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418011\" data-linked=\"FedEx off nearly 5% after cutting guidance; UPS dips alongside\" data-tweet=\"$FDX $FDX $UPS - FedEx off nearly 5% after cutting guidance; UPS dips alongside https://seekingalpha.com/news/3418011-fedex-off-nearly-5-after-cutting-guidance-ups-dips-alongside?source=tweet\" data-url=\"https://seekingalpha.com/news/3418011-fedex-off-nearly-5-after-cutting-guidance-ups-dips-alongside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>70&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418006\" data-ts=\"1545167847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTIC\" target=\"_blank\">CTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418006-cti-bio-sets-protocol-for-late-stage-study-of-pacritinib-in-myelofibrosis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CTI Bio sets protocol for late-stage study of pacritinib in myelofibrosis</a></h4><ul><li>Incorporating FDA feedback, CTI BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>) has <a href=\"https://seekingalpha.com/pr/17361983-cti-biopharma-provides-program-update-following-regulatory-feedback-u-s-fda-pacritinib\" target=\"_blank\">clarified </a>the principal design of a Phase 3 clinical trial evaluating pacritinib in adult patients with myelofibrosis who have severe thrombocytopenia (low blood platelets). The primary endpoint will be the proportion of patients who achieve at least a 35% reduction in spleen volume from baseline at week 24.</li><li>It will also amend the protocol in its Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03165734?lead=cti+biopharma&amp;rank=1\" target=\"_blank\">PAC203 </a>study to include a Phase 3 component that will enroll ~200 subjects beginning in Q3 2019.</li><li>The cost of the Phase 3 will be ~$25M. The company says its cash runway should extend into 2020.</li><li>Shares are down <font color=\"red\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418006\" data-linked=\"CTI Bio sets protocol for late-stage study of pacritinib in myelofibrosis\" data-tweet=\"$CTIC - CTI Bio sets protocol for late-stage study of pacritinib in myelofibrosis https://seekingalpha.com/news/3418006-cti-bio-sets-protocol-for-late-stage-study-of-pacritinib-in-myelofibrosis?source=tweet\" data-url=\"https://seekingalpha.com/news/3418006-cti-bio-sets-protocol-for-late-stage-study-of-pacritinib-in-myelofibrosis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417996\" data-ts=\"1545167242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417996-jabil-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil beats by $0.02, beats on revenue</a></h4><ul><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>): Q1 Non-GAAP EPS of $0.90 <span style=\"color:green\">beats by $0.02</span>; GAAP EPS of $0.76 <span style=\"color:green\">beats by $0.09</span>.</li><li>Revenue of $6.51B (+16.5% Y/Y) <font color=\"green\">beats by $410M</font>.</li><li>Shares <font color=\"green\">+3.6%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17361993-jabil-posts-record-first-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3417996\" data-linked=\"Jabil beats by $0.02, beats on revenue\" data-tweet=\"$JBL - Jabil beats by $0.02, beats on revenue https://seekingalpha.com/news/3417996-jabil-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3417996-jabil-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417978\" data-ts=\"1545163929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZS\" target=\"_blank\">ZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417978-needham-zscaler-heading-for-1b-in-reveneu-zsplus-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham: Zscaler heading for $1B in reveneu; ZS +2%</a></h4><ul><li>Needham reiterates Zscaler (NASDAQ:<a href='https://seekingalpha.com/symbol/ZS' title='Zscaler'>ZS</a>) at Strong Buy and a $47.50 target after meeting with the company.</li><li>Analyst Alex Henderson says ZS \"is poised to be a major leading cloud security company\" and thinks the company can deliver 30% to 50% annual growth over the next five years.</li><li>Henderson estimates that Zscaler could become a $1B revenue full SaaS cloud security company by 2022/2023 and a $2B company by the following years.</li><li>Source: Bloomberg First Word.</li><li>Zscaler shares are<font color=\"green\"> up 2.2%</font> to $39.12.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417978\" data-linked=\"Needham: Zscaler heading for $1B in reveneu; ZS +2%\" data-tweet=\"$ZS - Needham: Zscaler heading for $1B in reveneu; ZS +2% https://seekingalpha.com/news/3417978-needham-zscaler-heading-for-1b-in-reveneu-zsplus-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3417978-needham-zscaler-heading-for-1b-in-reveneu-zsplus-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417973\" data-ts=\"1545163337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRIN\" target=\"_blank\">MRIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417973-technology-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology movers and shakers</a></h4><ul><li><strong>Gainers: </strong>Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a>) <font color=\"green\">+48%</font>. The Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) <font color=\"green\">+16%</font>. Materialise NV (NASDAQ:<a href='https://seekingalpha.com/symbol/MTLS' title='Materialise NV'>MTLS</a>) <font color=\"green\">+15%</font>. One Stop Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/OSS' title='One Stop Systems, Inc.'>OSS</a>) <font color=\"green\">+12%</font>. SMART Global Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>OptimizeRx (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRX' title='OptimizeRx Corp.'>OPRX</a>) <font color=\"red\">-17%</font>. The9 Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-16%</font>. Sphere 3D (NASDAQ:<a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a>) <font color=\"red\">-13%</font>. Plug Power (NASDAQ:<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a>) <font color=\"red\">-10%</font>. Inpixon (NASDAQ:<a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a>) <font color=\"red\">-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417973\" data-linked=\"Technology movers and shakers\" data-tweet=\"$MRIN $MRIN $MEET - Technology movers and shakers https://seekingalpha.com/news/3417973-technology-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417973-technology-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417968\" data-ts=\"1545161848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARW\" target=\"_blank\">ARW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417968-arrow-electronics-amends-credit-facility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arrow Electronics amends its credit facility</a></h4><ul><li>Arrow Electronics (<a href='https://seekingalpha.com/symbol/ARW' title='Arrow Electronics Inc'>ARW</a> <font color='green'>+0.8%</font>) <a href=\"https://seekingalpha.com/pr/17361016-arrow-electronics-amended-credit-facility-increased-2-billion\" target=\"_blank\">amends</a> its revolving credit facility, extending the maturity to December 2023 and capacity to $2B from the previous December 2021 and $1.8B.</li><li>ARW is<font color=\"green\"> up 1%</font> to $70.56.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417968\" data-linked=\"Arrow Electronics amends its credit facility\" data-tweet=\"$ARW - Arrow Electronics amends its credit facility https://seekingalpha.com/news/3417968-arrow-electronics-amends-credit-facility?source=tweet\" data-url=\"https://seekingalpha.com/news/3417968-arrow-electronics-amends-credit-facility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417963\" data-ts=\"1545160287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417963-snap-hardware-unit-gets-another-new-boss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap hardware unit gets (another) new boss</a></h4><ul><li>Snap's (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) SnapLab hardware unit will have Steen Strand as its new boss in February, according to <a href=\"https://www.recode.net/2018/12/18/18145593/snap-spectacles-boss-replaced-sahil-sharma-steen-strand\" target=\"_blank\">Recode</a>. Strand, an Icon Aircraft vet, will be the unit's fourth boss in a little over a year.</li><li>VP of hardware development Sahil Sharma is leaving the company after joining in July to replace departing head Mark Randall.</li><li>Snap is reportedly working on a third version of its Spectacles, which were thought to arrive before the end of the year.</li><li>Snap shares are <font color=\"green\">up 3.9%</font> to $5.80.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417963\" data-linked=\"Snap hardware unit gets (another) new boss\" data-tweet=\"$SNAP - Snap hardware unit gets (another) new boss https://seekingalpha.com/news/3417963-snap-hardware-unit-gets-another-new-boss?source=tweet\" data-url=\"https://seekingalpha.com/news/3417963-snap-hardware-unit-gets-another-new-boss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417962\" data-ts=\"1545159874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBII\" target=\"_blank\">MBII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417962-commodities-among-energy-materials-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Commodities among Energy/Materials gainers</a></h4><ul><li><b>Gainers: </b>Marrone Bio Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a>) <font color=\"green\">+8%</font>. Alamos Gold (NYSE:<a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a>) <font color=\"green\">+8%</font>. Mountain Province Diamonds (NYSEMKT:<a href='https://seekingalpha.com/symbol/MPVD' title='Mountain Province Diamonds, Inc'>MPVD</a>) <font color=\"green\">+6%</font>. Approach Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/AREX' title='Approach Resources Inc.'>AREX</a>) <font color=\"green\">+5%</font>. Universal Stainless &amp; Alloy Products (NASDAQ:<a href='https://seekingalpha.com/symbol/USAP' title='Universal Stainless & Alloy Products, Inc.'>USAP</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>BP Prudhoe Bay Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/BPT' title='BP Prudhoe Bay Royalty Trust'>BPT</a>) <font color=\"red\">-14%</font>. NCS Multistage Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/NCSM' title='NCS Multistage Holdings'>NCSM</a>) <font color=\"red\">-13%</font>. Rosehill  Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a>) <font color=\"red\">-12%</font>. Blueknight Energy Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/BKEP' title='Blueknight Energy Partners'>BKEP</a>) <font color=\"red\">-11%</font>. Lonestar Resources US (NASDAQ:<a href='https://seekingalpha.com/symbol/LONE' title='Lonestar Resources US Inc.'>LONE</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417962\" data-linked=\"Commodities among Energy/Materials gainers\" data-tweet=\"$MBII $MBII $AGI - Commodities among Energy/Materials gainers https://seekingalpha.com/news/3417962-commodities-among-energy-materials-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417962-commodities-among-energy-materials-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417958\" data-ts=\"1545159381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417958-chips-gain-on-luxtera-acquisition-micron-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chips gain on Luxtera acquisition, Micron earnings</a></h4><ul><li>Chip stocks gain with the Philadelphia Semiconductor Index <font color=\"green\">up 2.2% </font>after Cisco announced plans to acquire Luxtera. Micron (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='green'>+2.1%</font>) will report earnings after the close today.</li><li>Barclays analyst Blayne Curtis says the purchase could <a href=\"https://thefly.com/landingPageNews.php?id=2838741&amp;headline=MTSI;CSCO;IPHI;INTC;MXIM-Cisco-acquisition-of-Luxtera-a-negative-for-Macom-says-Barclays\" target=\"_blank\">prove negative</a> for Macom (<a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a> <font color='green'>+2.3%</font>), which counts Cisco as the lead customer for its PSM4 solution and that MTSI doesn't seem to have much traction outside of Cisco on the product.</li><li>Curtis sees the acquisition as a modest long-term negative for Inphi (<a href='https://seekingalpha.com/symbol/IPHI' title='Inphi Corporation'>IPHI</a> <font color='green'>+2.1%</font>) and says it could put pressure on Intel (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='green'>+1.8%</font>) and Maxim Integrated (<a href='https://seekingalpha.com/symbol/MXIM' title='Maxim Integrated Products, Inc.'>MXIM</a> <font color='green'>+0.5%</font>).</li><li>B. Riley's Dave Kang <a href=\"https://thefly.com/landingPageNews.php?id=2838782&amp;headline=CSCO;AAOI;FNSR-Cisco-Applied-Optoelectronics-Finisar-analyst-commentary-\" target=\"_blank\">sees the acquisition</a> as negative for Finisar (<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='green'>+0.9%</font>) and Applied Optoelectronics (<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='red'>-8.6%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417817-cisco-will-acquire-luxtera-660m\" target=\"_blank\">Cisco will acquire Luxtera for $660M</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417958\" data-linked=\"Chips gain on Luxtera acquisition, Micron earnings\" data-tweet=\"$MU $MU $MTSI - Chips gain on Luxtera acquisition, Micron earnings https://seekingalpha.com/news/3417958-chips-gain-on-luxtera-acquisition-micron-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3417958-chips-gain-on-luxtera-acquisition-micron-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417953\" data-ts=\"1545158028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WPG\" target=\"_blank\">WPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417953-washington-prime-sinks-after-goldman-downgrades-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Washington Prime sinks after Goldman downgrades to sell</a></h4><ul><li>Washington Prime Group (<a href='https://seekingalpha.com/symbol/WPG' title='Washington Prime Group, Inc.'>WPG</a> <font color='red'>-8.1%</font>) slumps after Goldman Sachs <a href=\"https://www.marketbeat.com/ratings/USA/latest/\" target=\"_blank\">cuts rating</a> to sell from neutral.</li><li>Price target cut to $4.30 from $6.60.</li><li>Earlier WPG touched $5.25, a new 52-week low.</li><li>Mall REITs CBL (<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a> <font color='red'>-10.2%</font>) and Pennsylvania REIT (<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a> <font color='red'>-4.5%</font>) also sink. All three REITs have exposure to Sears, which has a <a href=\"https://restructuring.primeclerk.com/sears/Home-DocketInfo\" target=\"_blank\">bankruptcy hearing</a> today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3396418-cbl-seen-risk-macerich-best-position-post-sears-bankruptcy\" target=\"_blank\">CBL seen most at risk, Macerich in best position post-Sears bankruptcy</a> (Oct. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417953\" data-linked=\"Washington Prime sinks after Goldman downgrades to sell\" data-tweet=\"$WPG $WPG $CBL - Washington Prime sinks after Goldman downgrades to sell https://seekingalpha.com/news/3417953-washington-prime-sinks-after-goldman-downgrades-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3417953-washington-prime-sinks-after-goldman-downgrades-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>83&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417950\" data-ts=\"1545157863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APHA\" target=\"_blank\">APHA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417950-aphria-up-10-on-positive-citron-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aphria up 10% on positive Citron report</a></h4><ul><li>Pot stock Aphria (<a href='https://seekingalpha.com/symbol/APHA' title='Aphria Inc.'>APHA</a> <font color=\"green\">+9.9%</font>) is up on almost 7M shares on the heels of a <a href=\"https://citronresearch.com/wp-content/uploads/2018/12/Everything-Has-Changed-The-Big-5-Canadian-Cannabis-Companies-Have-Achieved-Platform-Status.pdf\" target=\"_blank\">bullish report</a> from Citron Research who says the stock could jump <font color=\"green\">33%</font> to $8 by month-end.</li><li>Citron says the company sports an attractive valuation ($1.5B) relative to peers Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color=\"green\">+4.2%</font>) ($2.1B), Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) ($10.7B), Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"green\">+1.1%</font>) ($5.6B) and Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"green\">+17.8%</font>) ($7.3B) and may be an acquisition target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417950\" data-linked=\"Aphria up 10% on positive Citron report\" data-tweet=\"$APHA $APHA $CRON - Aphria up 10% on positive Citron report https://seekingalpha.com/news/3417950-aphria-up-10-on-positive-citron-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3417950-aphria-up-10-on-positive-citron-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417949\" data-ts=\"1545157721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGH\" target=\"_blank\">SGH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417949-smart-globalplus-11-on-joining-s-and-p-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smart Global +11% on joining S&amp;P SmallCap 600</a></h4><ul><li>Smart Global (NASDAQ:<a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a>) <font color=\"green\">gains 10.9%</font> <a href=\"https://www.prnewswire.com/news-releases/smart-global-holdings-set-to-join-sp-smallcap-600-300767800.html\" target=\"_blank\">on news</a> the company will join the S&amp;P SmallCap 600 Index, effective December 24.</li><li>Smart Global will replace XO Group, which is being acquired by WeddingWire.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417949\" data-linked=\"Smart Global +11% on joining S&amp;P SmallCap 600\" data-tweet=\"$SGH - Smart Global +11% on joining S&amp;P SmallCap 600 https://seekingalpha.com/news/3417949-smart-globalplus-11-on-joining-s-and-p-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3417949-smart-globalplus-11-on-joining-s-and-p-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417945\" data-ts=\"1545156208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVER\" target=\"_blank\">EVER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417945-everquote-leads-financial-gainers-exp-world-holdings-and-washington-prime-group-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EverQuote leads financial gainers; eXp World Holdings and Washington Prime Group among losers</a></h4><ul><li><b>Gainers:</b> EverQuote (NASDAQ:<a href='https://seekingalpha.com/symbol/EVER' title='EverQuote'>EVER</a>) <font color=\"green\">+8%</font>. Mesabi Trust (NYSE:<a href='https://seekingalpha.com/symbol/MSB' title='Mesabi Trust'>MSB</a>) <font color=\"green\">+7%</font>. Shore Bancshares (NASDAQ:<a href='https://seekingalpha.com/symbol/SHBI' title='Shore Bancshares Inc'>SHBI</a>) <font color=\"green\">+7%</font>. Ashford Hospitality Trust (NYSE:<a href='https://seekingalpha.com/symbol/AHT' title='Ashford Hospitality Trust, Inc.'>AHT</a>) <font color=\"green\">+7%</font>. Owens Realty Mortgage (NYSEMKT:<a href='https://seekingalpha.com/symbol/ORM' title='Owens Realty Mortgage, Inc.'>ORM</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> B. Riley Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/RILY' title='B. Riley Financial, Inc.'>RILY</a>) <font color=\"red\">-9%</font>. Washington Prime Group (NYSE:<a href='https://seekingalpha.com/symbol/WPG' title='Washington Prime Group, Inc.'>WPG</a>) <font color=\"red\">-8%</font>. eXp World Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/EXPI' title='eXp World Holdings, Inc.'>EXPI</a>) <font color=\"red\">-7%</font>. CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a>) <font color=\"red\">-7%</font>. CNFinance Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CNF' title='CNFinance Holdings'>CNF</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417945\" data-linked=\"EverQuote leads financial gainers; eXp World Holdings and Washington Prime Group among losers\" data-tweet=\"$EVER $EVER $MSB - EverQuote leads financial gainers; eXp World Holdings and Washington Prime Group among losers https://seekingalpha.com/news/3417945-everquote-leads-financial-gainers-exp-world-holdings-and-washington-prime-group-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417945-everquote-leads-financial-gainers-exp-world-holdings-and-washington-prime-group-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417942\" data-ts=\"1545155631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRIN\" target=\"_blank\">MRIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417942-healthcare-tech-leads-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare &amp; Tech leads midday movers</a></h4><ul><li><strong>Gainers: </strong>Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a>) <font color=\"green\">+45%</font>. HyreCar (NASDAQ:<a href='https://seekingalpha.com/symbol/HYRE' title='HyreCar'>HYRE</a>) <font color=\"green\">+26%</font>. The Lovesac (NASDAQ:<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a>) <font color=\"green\">+19%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp. Ltd.'>SOLO</a>) <font color=\"green\">+17%</font>. The Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) <font color=\"green\">+16%</font>. Tyme Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TYME' title='Tyme Technologies, Inc.'>TYME</a>) <font color=\"green\">+12%</font>. Diebold Nixdorf (NYSE:<a href='https://seekingalpha.com/symbol/DBD' title='Diebold Nixdorf'>DBD</a>) <font color=\"green\">+12%</font>. Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) <font color=\"green\">+12%</font>. Materialise NV (NASDAQ:<a href='https://seekingalpha.com/symbol/MTLS' title='Materialise NV'>MTLS</a>) <font color=\"green\">+11%</font>. SMART Global Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/SGH' title='SMART Global Holdings'>SGH</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>Nemaura Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/NMRD' title='Nemaura Medical, Inc.'>NMRD</a>) <font color=\"red\">-39%</font>. AxoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/AXGN' title='AxoGen, Inc.'>AXGN</a>) <font color=\"red\">-27%</font>. Xcel Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a>) <font color=\"red\">-24%</font>. Aileron Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a>) <font color=\"red\">-23%</font>. Dova Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DOVA' title='Dova Pharmaceuticals'>DOVA</a>) <font color=\"red\">-22%</font>. Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc'>MBOT</a>) <font color=\"red\">-21%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a>) <font color=\"red\">-19%</font>. ContraFect (NASDAQ:<a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a>) <font color=\"red\">-19%</font>. Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) <font color=\"red\">-18%</font>. Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) <font color=\"red\">-16%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417942\" data-linked=\"Healthcare &amp; Tech leads midday movers\" data-tweet=\"$MRIN $MRIN $HYRE - Healthcare &amp; Tech leads midday movers https://seekingalpha.com/news/3417942-healthcare-tech-leads-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417942-healthcare-tech-leads-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417941\" data-ts=\"1545155391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXGN\" target=\"_blank\">AXGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417941-axogen-down-27-on-bearish-sa-article\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AxoGen down 27% on bearish SA article</a></h4><ul><li>AxoGen (<a href='https://seekingalpha.com/symbol/AXGN' title='AxoGen, Inc.'>AXGN</a> <font color=\"red\">-27%</font>) slumps on triple normal on the heels of an <a href=\"https://seekingalpha.com/article/4228960-axogen-overhyped-cash-burning-reverse-merger-12x-revenue-5_07-target-price-82-percent\" target=\"_blank\">article </a>published today on Seeking Alpha by Seligman Investments saying its cadaver-sourced nerve grafts are over-hyped, citing modest revenues of $78M 11 years post-launch in an addressable market valued at $2.7B.</li><li>Seligman believes the company's fair value target is $5.07, almost 75% below the current price of $19.80.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417941\" data-linked=\"AxoGen down 27% on bearish SA article\" data-tweet=\"$AXGN - AxoGen down 27% on bearish SA article https://seekingalpha.com/news/3417941-axogen-down-27-on-bearish-sa-article?source=tweet\" data-url=\"https://seekingalpha.com/news/3417941-axogen-down-27-on-bearish-sa-article\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417937\" data-ts=\"1545153730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALRN\" target=\"_blank\">ALRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417937-aileron-continues-selloff-down-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aileron continues selloff, down 24%</a></h4><ul><li>Thinly traded nano cap Aileron Therapeutics (<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a> <font color=\"red\">-23.8%</font>) continues its downward fall on more than triple normal volume. Shares have lost over <font color=\"red\">60%</font> of their value this month.</li><li>Lead candidate is ALRN-6924, in Phase 1 or 2 development for a range of solid tumors and blood cancers.</li><li>On the working capital front, at the end of September it had $27.9M in quick assets while operations consumed $21.3M during the first three quarters of the year.</li><li>The company is currently selling for less than the $1.90 cash value per share at the end of Q3.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417937\" data-linked=\"Aileron continues selloff, down 24%\" data-tweet=\"$ALRN - Aileron continues selloff, down 24% https://seekingalpha.com/news/3417937-aileron-continues-selloff-down-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3417937-aileron-continues-selloff-down-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417938\" data-ts=\"1545153521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVI\" target=\"_blank\">NAVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417938-navient-must-face-state-suit-on-predatory-student-loans-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navient must face state suit on `predatory&#39; student loans: Bloomberg</a></h4><ul><li>Navient Corp. (NASDAQ:<a href='https://seekingalpha.com/symbol/NAVI' title='Navient Corp'>NAVI</a>) <a href=\"https://www.bloomberg.com/news/articles/2018-12-18/navient-must-face-state-s-suit-on-predatory-student-loan-plans?cmpid=socialflow-twitter-business&amp;utm_medium=social&amp;utm_content=business&amp;utm_source=twitter&amp;utm_campaign=socialflow-organic\" target=\"_blank\">must face a lawsuit </a>filed by the state of Pennsylvania alleging \"deceptive practices and predatory conduct,\" Bloomberg reports.</li><li>Navient<font color=\"red\"> -0.8%</font> in midday trading.</li><li>The biggest servicer of U.S. student loans will have to face claims that it violated consumer protection laws by steering struggling borrowers into payment plans that benefited the company rather than the students, according to a ruling late Monday by U.S. District Judge Robert Mariani in Scranton.</li><li>Navient's earlier motions to dismiss the claims failed in three similar cases.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417197-barclays-trims-navient-target\" target=\"_blank\">Barclays trims its Navient target</a> (Dec. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417938\" data-linked=\"Navient must face state suit on `predatory&#39; student loans: Bloomberg\" data-tweet=\"$NAVI - Navient must face state suit on `predatory&#39; student loans: Bloomberg https://seekingalpha.com/news/3417938-navient-must-face-state-suit-on-predatory-student-loans-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3417938-navient-must-face-state-suit-on-predatory-student-loans-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417935\" data-ts=\"1545153141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOVE\" target=\"_blank\">LOVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417935-lovesac-jumpsplus-11-on-q3-result-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lovesac jumps +11% on Q3 result beats</a></h4><ul><li>The Lovesac (<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a> <font color=\"green\">+11.1%</font>) reported Q3 sales growth of 70.9% Y/Y to $41.7M, driven by strong showroom, Internet and shop-in-shop performance.</li><li>Combined Comparable sales increased 51.0% Y/Y, with comparable showroom sales +40.5% Y/Y and Internet sales +93.9% Y/Y.</li><li>Q3 Gross margin <font color=\"red\">declined by 113 bps</font> to 54.9% and operating loss increased 30.5% Y/Y to $2.7M.</li><li>Company reported Adj. EBITDA loss of $392k, compared to $778k a year ago.</li><li>SG&amp;A expenses increased 59.8% Y/Y to $19.33M and margin declined by 322 bps to 46.4%.</li><li>Net cash used in operating activities YTD was $14.22M, compared to $9.49M a year ago.</li><li>Company has Cash and cash equivalents of $44.68M as of November 4, 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417773-lovesac-beats-0_05-beats-revenue\" target=\"_blank\">Lovesac beats by $0.05, beats on revenue</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417935\" data-linked=\"Lovesac jumps +11% on Q3 result beats\" data-tweet=\"$LOVE - Lovesac jumps +11% on Q3 result beats https://seekingalpha.com/news/3417935-lovesac-jumpsplus-11-on-q3-result-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3417935-lovesac-jumpsplus-11-on-q3-result-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417934\" data-ts=\"1545152748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOLO\" target=\"_blank\">SOLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417934-navistar-international-among-consumer-gainers-orchids-paper-products-and-sorl-auto-parts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navistar International among consumer gainers; Orchids Paper Products and SORL Auto Parts among losers</a></h4><ul><li><b>Gainers: </b>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp. Ltd.'>SOLO</a>) <font color=\"green\">+16%</font>. Navistar International (NYSE:<a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a>) <font color=\"green\">+11%</font>. The Lovesac (NASDAQ:<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a>) <font color=\"green\">+10%</font>. Calyxt (NASDAQ:<a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a>) <font color=\"green\">+7%</font>. Farmmi (NASDAQ:<a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi Inc.'>FAMI</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Xcel Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a>) <font color=\"red\">-23%</font>. Ballantyne Strong (NYSEMKT:<a href='https://seekingalpha.com/symbol/BTN' title='Ballantyne Strong, Inc.'>BTN</a>) <font color=\"red\">-12%</font>. Seneca Foods (NASDAQ:<a href='https://seekingalpha.com/symbol/SENEA' title='Seneca Foods Corp.'>SENEA</a>) <font color=\"red\">-8%</font>. SORL Auto Parts (NASDAQ:<a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a>) <font color=\"red\">-6%</font>. Orchids Paper Products (NYSEMKT:<a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417934\" data-linked=\"Navistar International among consumer gainers; Orchids Paper Products and SORL Auto Parts among losers\" data-tweet=\"$SOLO $SOLO $NAV - Navistar International among consumer gainers; Orchids Paper Products and SORL Auto Parts among losers https://seekingalpha.com/news/3417934-navistar-international-among-consumer-gainers-orchids-paper-products-and-sorl-auto-parts?source=tweet\" data-url=\"https://seekingalpha.com/news/3417934-navistar-international-among-consumer-gainers-orchids-paper-products-and-sorl-auto-parts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417933\" data-ts=\"1545152604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRX\" target=\"_blank\">CPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417933-catalyst-pharma-up-5-on-endo-deal-for-generic-sabril\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Pharma up 5% on Endo deal for generic Sabril</a></h4><ul><li>Catalyst Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CPRX' title='Catalyst Pharmaceuticals, Inc.'>CPRX</a> <font color=\"green\">+4.9%</font>) is up on average volume in reaction to its <a href=\"https://seekingalpha.com/pr/17361697-catalyst-pharmaceuticals-announces-definitive-agreement-endo-vigabatrin-tablets\" target=\"_blank\">agreement </a>with Endo International (<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color=\"red\">-0.1%</font>) to develop and commercialize its generic version of Lundbeck's (<a href='https://seekingalpha.com/symbol/HLUYY' title='H. Lundbeck A/S ADR'>OTCPK:HLUYY</a> <font color=\"green\">+2.6%</font>) epilepsy med <a href=\"https://www.sabril.net/\" target=\"_blank\">Sabril</a> (vigabatrin) through its Par Pharmaceutical unit.</li><li>Under the terms of the contract, CPRX will receive an upfront payment, milestones and a share of the profits when commercialized. Specific financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417933\" data-linked=\"Catalyst Pharma up 5% on Endo deal for generic Sabril\" data-tweet=\"$CPRX $CPRX $ENDP - Catalyst Pharma up 5% on Endo deal for generic Sabril https://seekingalpha.com/news/3417933-catalyst-pharma-up-5-on-endo-deal-for-generic-sabril?source=tweet\" data-url=\"https://seekingalpha.com/news/3417933-catalyst-pharma-up-5-on-endo-deal-for-generic-sabril\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417930\" data-ts=\"1545152251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GT\" target=\"_blank\">GT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417930-goodyear-tire-rubber-to-expand-capacity-slovenian-facility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goodyear Tire &amp; Rubber to expand capacity at Slovenian facility</a></h4><ul><li>Goodyear Tire &amp; Rubber (<a href='https://seekingalpha.com/symbol/GT' title='Goodyear Tire & Rubber Co.'>GT</a> <font color='green'>+1.6%</font>) announces plans to expand its manufacturing facility in Slovenia to meet the growing demand for premium tires in the Europe/Middle East/Asia business.</li> <li>\"The demand for premium, larger-rim-diameter consumer tires is growing across EMEA. To ensure the sustainable growth of our business, Goodyear plans to invest \u20ac94 million in its plant in Kranj, Slovenia to increase its capacity in this profitable segment,\" says Gooyear VP Henry Dumortier.</li><li>Goodyear's Vice President Consumer Europe.</li><li>The investment will help increase the plant's overall capacity by approximately 25% to allow for production of an additional 1.8M premium, A segment consumer tires annually.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17361665-goodyear-expand-capacity-slovenian-manufacturing-facility\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3417930\" data-linked=\"Goodyear Tire &amp; Rubber to expand capacity at Slovenian facility\" data-tweet=\"$GT - Goodyear Tire &amp; Rubber to expand capacity at Slovenian facility https://seekingalpha.com/news/3417930-goodyear-tire-rubber-to-expand-capacity-slovenian-facility?source=tweet\" data-url=\"https://seekingalpha.com/news/3417930-goodyear-tire-rubber-to-expand-capacity-slovenian-facility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417928\" data-ts=\"1545152039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417928-biogen-down-5-sell-siders-soften-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen down 5%, sell-siders soften outlook</a></h4><ul><li>Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color=\"red\">-5.3%</font>) is down on average volume, almost completing a round turn from a brief rally that began in October.</li><li>This quarter, Oppenheimer, RBC and JPMorgan all lowered their price targets (although two of three maintain their Buy ratings). Bernstein is the most bearish, citing patent risks for Tecfidera and potentially futile results for Alzheimer's candidate aducanumab that could drive the stock down to the $100 range.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417928\" data-linked=\"Biogen down 5%, sell-siders soften outlook\" data-tweet=\"$BIIB - Biogen down 5%, sell-siders soften outlook https://seekingalpha.com/news/3417928-biogen-down-5-sell-siders-soften-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3417928-biogen-down-5-sell-siders-soften-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417921\" data-ts=\"1545149802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBA\" target=\"_blank\">AMBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417921-analyst-positive-on-ambarellas-hella-deal-ambaplus-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst positive on Ambarella&#39;s Hella deal; AMBA +3%</a></h4><ul><li>Morgan Stanley analyst Joseph Moore says Ambarella (NASDAQ:<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella'>AMBA</a>) deal with Hella to <a href=\"https://seekingalpha.com/pr/17359593-ambarella-hella-aglaia-partner-enable-advanced-ai-features-front-adas-cameras\" target=\"_blank\">deliver a platform</a> for next-gen advanced driver assistance systems has substantial strategic value and \"will take on Mobileye (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) for 2021 model year and beyond.\"</li><li>Moore says it will take time for this to drive revenue growth, but he expects strength in the auto segment in the interim.</li><li>AMBA remains the firm's favorite small cap idea, despite recent pressures.</li><li>Rating maintained at Overweight with a $50 target.</li><li>Source: Bloomberg First Word.</li><li>AMBA shares are <font color=\"green\">up 3%</font> to $38.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417921\" data-linked=\"Analyst positive on Ambarella&#39;s Hella deal; AMBA +3%\" data-tweet=\"$AMBA $AMBA $INTC - Analyst positive on Ambarella&#39;s Hella deal; AMBA +3% https://seekingalpha.com/news/3417921-analyst-positive-on-ambarellas-hella-deal-ambaplus-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3417921-analyst-positive-on-ambarellas-hella-deal-ambaplus-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417919\" data-ts=\"1545149391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417919-blue-apron-drops-below-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron drops below $1</a></h4><ul> <li>Shares of Blue Apron (<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color=\"red\">-8%</font>) slip below $1 for the first and traded as low as $0.884 earlier in the session.</li> <li>Blue Apron is now trading below even the lowest price target set by Wall Street analysts.</li> <li>The meal kit provider priced its IPO at $10 per share last year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417919\" data-linked=\"Blue Apron drops below $1\" data-tweet=\"$APRN - Blue Apron drops below $1 https://seekingalpha.com/news/3417919-blue-apron-drops-below-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3417919-blue-apron-drops-below-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417915\" data-ts=\"1545149241\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417915-tilray-and-equillium-among-healthcare-gainers-contrafect-and-diffusion-pharmaceuticals-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray and Equillium among healthcare gainers; ContraFect and Diffusion Pharmaceuticals among losers</a></h4><ul><li><b>Gainers: </b>CollPlant Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CLGN' title='CollPlant'>CLGN</a>) <font color=\"green\">+14%</font>. Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) <font color=\"green\">+9%</font>. Equillium (NASDAQ:<a href='https://seekingalpha.com/symbol/EQ' title='Equillium'>EQ</a>) <font color=\"green\">+8%</font>. Kodiak Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/KOD' title='Kodiak Sciences'>KOD</a>) <font color=\"green\">+5%</font>. Tyme Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TYME' title='Tyme Technologies, Inc.'>TYME</a>) <font color=\"green\">5</font><font color=\"green\">%</font>.</li><li><b>Losers: </b>Nemaura Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/NMRD' title='Nemaura Medical, Inc.'>NMRD</a>) <font color=\"red\">-39%</font>. ContraFect (NASDAQ:<a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corp.'>CFRX</a>) <font color=\"red\">-25%</font>. Aileron Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ALRN' title='Aileron Therapeutics'>ALRN</a>) <font color=\"red\">-24%</font>. Champions Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CSBR' title='Champions Oncology, Inc.'>CSBR</a>) <font color=\"red\">-19%</font>. Diffusion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417915\" data-linked=\"Tilray and Equillium among healthcare gainers; ContraFect and Diffusion Pharmaceuticals among losers\" data-tweet=\"$TLRY $CLGN $TLRY - Tilray and Equillium among healthcare gainers; ContraFect and Diffusion Pharmaceuticals among losers https://seekingalpha.com/news/3417915-tilray-and-equillium-among-healthcare-gainers-contrafect-and-diffusion-pharmaceuticals-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3417915-tilray-and-equillium-among-healthcare-gainers-contrafect-and-diffusion-pharmaceuticals-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417904\" data-ts=\"1545148382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEI\" target=\"_blank\">HEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417904-heico-up-6-on-q4-result-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heico up 6% on Q4 result beats</a></h4><ul><li>Heico (<a href='https://seekingalpha.com/symbol/HEI' title='HEICO Corporation'>HEI</a> <font color=\"green\">+6%</font>) reported Q4 net sales growth of 13.2% Y/Y to $476.88M. Sales by segments: Flight support group $290.25M (+13% Y/Y) and Electronic technologies group $191.08M (+13.02% Y/Y).</li><li>Q4 Operating margin <font color=\"green\">improved by 50 bps</font> to 21.7%.</li><li>EBITDA increased by 14.6% Y/Y to $123.31M and margin <font color=\"green\">improved by 31 bps</font> to 25.9%.</li><li>Flight support group operating margin <font color=\"green\">improved by 70 bps</font> to 18.8% and Electronic technologies group <font color=\"red\">declined by 26 bps </font>to 29.9%.</li><li>SG&amp;A expenses increased by 17.3% Y/Y to $82.76M.</li><li>Net cash provided by operating activities YTD was $328.49M, compared to $288.28M a year ago.</li><li>Company has Cash and cash equivalents of $59.59M as of October 31, 2018.</li><li><strong>FY19 Guidance:</strong> Net sales growth 8-10%; net income ~10% growth; operating margin ~21-21.5%; Capex ~$48M and cash flow from operations ~$360M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417434-heico-declares-0_07-dividend\" target=\"_blank\">HEICO declares $0.07 dividend</a> (Dec. 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417662-heico-beats-0_01-beats-revenue\" target=\"_blank\">HEICO beats by $0.01, beats on revenue</a> (Dec. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417904\" data-linked=\"Heico up 6% on Q4 result beats\" data-tweet=\"$HEI - Heico up 6% on Q4 result beats https://seekingalpha.com/news/3417904-heico-up-6-on-q4-result-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3417904-heico-up-6-on-q4-result-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417900\" data-ts=\"1545147651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417900-helios-matheson-analytics-updates-on-note-exchange\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helios &amp; Matheson Analytics updates on note exchange</a></h4><ul> <li>Helios &amp; Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) discloses an exchange of the remaining amount payable on its $18.8M November convertible notes and its $25.7 million January convertible note for about $11.3M in new non-convertible Series B senior notes.</li> <li><a href=\"https://seekingalpha.com/filing/4273275\" target=\"_blank\">SEC Form 8-K</a></li> <li>HMNY trades at $0.02.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417900\" data-linked=\"Helios &amp; Matheson Analytics updates on note exchange\" data-tweet=\"$HMNY - Helios &amp; Matheson Analytics updates on note exchange https://seekingalpha.com/news/3417900-helios-matheson-analytics-updates-on-note-exchange?source=tweet\" data-url=\"https://seekingalpha.com/news/3417900-helios-matheson-analytics-updates-on-note-exchange\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417899\" data-ts=\"1545147559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417899-bernstein-bull-lowers-netflix-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bernstein bull lowers Netflix target</a></h4><ul><li>Bernstein analyst Todd Juenger maintains an Outperform rating for Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) but lowers the target from $465 to $421.</li><li>The analyst is grappling with the \"especially tough question\" of what's already priced into the stock, saying the market is no longer buying into the idea that higher programming spend is necessary to build subscribers.</li><li>Juenger remains positive on subscriber numbers beating expectations.</li><li>Source: Bloomberg First Word.</li><li>Netflix shares are <font color=\"green\">up 2%</font> to $268.01.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417899\" data-linked=\"Bernstein bull lowers Netflix target\" data-tweet=\"$NFLX - Bernstein bull lowers Netflix target https://seekingalpha.com/news/3417899-bernstein-bull-lowers-netflix-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3417899-bernstein-bull-lowers-netflix-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417896\" data-ts=\"1545147029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TER\" target=\"_blank\">TER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417896-teradyneplus-4-on-northland-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teradyne +4% on Northland initiation</a></h4><ul><li>Northland Securities <a href=\"https://www.streetinsider.com/Analyst+Comments/Northland+Capital+Markets+Starts+Teradyne+%28TER%29+at+Market+Perform/14932033.html\" target=\"_blank\">starts</a> Teradyne (NYSE:<a href='https://seekingalpha.com/symbol/TER' title='Teradyne Inc.'>TER</a>) at Market Perform with a $35 price target, a 10% upside to yesterday's close.</li><li>Analyst Gus Richard says the company is \"a leading supplier of semiconductor test equipment and an emerging supplier of industrial robots.\"</li><li>The analyst expects 1H19 weakness on inventory correction but a strong 5G product cycle moving into CY20.</li><li>The firm thinks Teradyne's CAGR will accelerate into the low-double digits in CY20 and beyond.</li><li>Teradyne shares are <font color=\"green\">up 4.3%</font> to $33.15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417896\" data-linked=\"Teradyne +4% on Northland initiation\" data-tweet=\"$TER - Teradyne +4% on Northland initiation https://seekingalpha.com/news/3417896-teradyneplus-4-on-northland-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3417896-teradyneplus-4-on-northland-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417894\" data-ts=\"1545146396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417894-navistar-results-spark-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navistar results spark rally</a></h4><ul> <li>Navistar (<a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+18.8%</font>) soars after strong results and a confident outlook for 2019 brings investors rushing back in.</li> <li>Analysts are pointing in particular to the impressive 20% jump in adjusted EBITDA during the quarter and solid backlog of orders heading into next year.</li> <li>Riding on the coattails of Navistar are PACCAR (<a href='https://seekingalpha.com/symbol/PCAR' title='PACCAR Inc.'>PCAR</a> <font color='green'>+2%</font>), Oshkosh (<a href='https://seekingalpha.com/symbol/OSK' title='Oshkosh Corporation'>OSK</a> <font color='green'>+3%</font>), Meritor (<a href='https://seekingalpha.com/symbol/MTOR' title='Meritor, Inc.'>MTOR</a> <font color='green'>+3.2%</font>), Cummins (<a href='https://seekingalpha.com/symbol/CMI' title='Cummins Inc.'>CMI</a> <font color='green'>+1.6%</font>), Allison Transmission (<a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a> <font color='green'>+2.7%</font>), WABCO (<a href='https://seekingalpha.com/symbol/WBC' title='WABCO Holdings Inc.'>WBC</a> <font color='green'>+1.5%</font>) and Wabash National (<a href='https://seekingalpha.com/symbol/WNC' title='Wabash National Corporation'>WNC</a> <font color='green'>+3.1%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417772-navistar-strikes-gains-fq4\" target=\"_blank\">Navistar strikes gains in FQ4</a> (Dec. 18)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417894\" data-linked=\"Navistar results spark rally\" data-tweet=\"$NAV $NAV $PCAR - Navistar results spark rally https://seekingalpha.com/news/3417894-navistar-results-spark-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/3417894-navistar-results-spark-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417878\" data-ts=\"1545145446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAK\" target=\"_blank\">TAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417878-takeda-52-week-low-after-moodys-downgrade-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Takeda at 52-week low after Moody&#39;s downgrade; shares down 5%</a></h4><ul><li>Takeda Pharmaceutical Company (TKPYY <font color=\"red\">-4.6%</font>) is down on light volume in early trade. Shares are currently exchanging hands at a 52-week low as it advances its planned $62B takeout of Shire plc, expected to close in the next few weeks.</li><li>Yesterday, Moody's <a href=\"https://www.moodys.com/credit-ratings/Takeda-Pharmaceutical-Company-Limited-credit-rating-3039\" target=\"_blank\">downgraded </a>its credit rating to Baa2 with a stable outlook.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417878\" data-linked=\"Takeda at 52-week low after Moody&#39;s downgrade; shares down 5%\" data-tweet=\"$TAK - Takeda at 52-week low after Moody&#39;s downgrade; shares down 5% https://seekingalpha.com/news/3417878-takeda-52-week-low-after-moodys-downgrade-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3417878-takeda-52-week-low-after-moodys-downgrade-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417877\" data-ts=\"1545144966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417877-stocks-gain-strongly-after-blue-monday\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks gain strongly after blue Monday</a></h4><ul><li>U.S. stock markets start strongly, led by industrial goods (<font color=\"green\">+1.6%</font>), tech (<font color=\"green\">+1.1%</font>), and financial (<font color=\"green\">+1.0%</font>).</li><li>S&amp;P 500 <font color=\"green\">1.1%</font>, Nasdaq <font color=\"green\">+1.1%</font>, Dow <font color=\"green\">+1.4%</font>.</li><li>Individual names gaining include Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color=\"green\">+1.8%</font>), Alphabet (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color=\"green\">+1.6%</font>), Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color=\"green\">+4.8%</font>), Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color=\"green\">+2.4%</font>).</li><li>J&amp;J (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color=\"green\">+1%</font>) rebounds as it announces a <a href=\"https://seekingalpha.com/news/3417684-johnson-and-johnson-oks-5b-stock-buyback-program\" target=\"_blank\">$5B stock buyback</a>; follows a sharp two-day decline on a Reuters story <a href=\"https://seekingalpha.com/news/3417609-j-and-j-chief-gorsky-defends-talc-powder-shares-remain-pressure-4-percent\" target=\"_blank\">alleging </a>asbestos was found in the company's baby powder.</li><li>Oracle (<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a> <font color=\"green\">+3.8%</font>) gains after providing<a href=\"https://seekingalpha.com/news/3417788-oracle-provides-upside-q3-guidance-shares-plus-5-percent\" target=\"_blank\"> better-than-expected</a> Q3 guidance.</li><li>Crude <font color=\"red\">falls 3.1%</font> to $48.36; prices drop to a 14-month low.</li><li>U.S. dollar index <font color=\"red\">falls 0.2%</font> to 96.98.</li><li>U.S. 10-year Treasury bid up, pushing yield down almost 1 basis point to 2.85%; 2-year Treasury yield also down almost 1 basis point at 2.687%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417877\" data-linked=\"Stocks gain strongly after blue Monday\" data-tweet=\"$AMZN $AMZN $GOOG - Stocks gain strongly after blue Monday https://seekingalpha.com/news/3417877-stocks-gain-strongly-after-blue-monday?source=tweet\" data-url=\"https://seekingalpha.com/news/3417877-stocks-gain-strongly-after-blue-monday\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417867\" data-ts=\"1545143950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KODK\" target=\"_blank\">KODK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417867-ftc-grants-antitrust-clearance-for-flexographic-packaging-division-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTC grants antitrust clearance for Flexographic Packaging Division sale</a></h4><ul><li>Kodak (<a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Co.'>KODK</a> <font color=\"green\">+1%</font>) received <a href=\"https://www.ftc.gov/enforcement/premerger-notification-program/early-termination-notices/20190487\" target=\"_blank\">FTC clearance</a> for the <a href=\"https://seekingalpha.com/news/3408460-kodak-plus-10-percent-asset-sale\" target=\"_blank\">sale</a> of their Flexographic Packaging Division to PE firm Montagu Private Equity.</li><li>Kodak intends to use the proceeds from the sale to reduce long-term debt.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417867\" data-linked=\"FTC grants antitrust clearance for Flexographic Packaging Division sale\" data-tweet=\"$KODK - FTC grants antitrust clearance for Flexographic Packaging Division sale https://seekingalpha.com/news/3417867-ftc-grants-antitrust-clearance-for-flexographic-packaging-division-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3417867-ftc-grants-antitrust-clearance-for-flexographic-packaging-division-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417860\" data-ts=\"1545143028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPRX\" target=\"_blank\">OPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417860-optimizerx-prices-equity-offering-shares-down-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OptimizeRx prices equity offering; shares down 16% premarket</a></h4><ul><li>OptimizeRx (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRX' title='OptimizeRx Corp.'>OPRX</a>) <a href=\"https://seekingalpha.com/pr/17361239-optimizerx-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices</a> its public offering of ~2.1M common shares from a current investor at $10 per share. Underwriters over-allotment is an additional ~316K shares. Closing date is December 20.</li><li>The company will receive no proceeds from the sales.</li><li>Shares are down <font color=\"red\">16%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417860\" data-linked=\"OptimizeRx prices equity offering; shares down 16% premarket\" data-tweet=\"$OPRX - OptimizeRx prices equity offering; shares down 16% premarket https://seekingalpha.com/news/3417860-optimizerx-prices-equity-offering-shares-down-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3417860-optimizerx-prices-equity-offering-shares-down-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417859\" data-ts=\"1545142764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRBP\" target=\"_blank\">CRBP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417859-corbus-pharma-up-3-premarket-on-new-lenabasum-patent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corbus Pharma up 3% premarket on new lenabasum patent</a></h4><ul><li>Corbus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a>) is up <font color=\"green\">3%</font> premarket on light volume in reaction to the <a href=\"https://seekingalpha.com/pr/17361235-corbus-pharmaceuticals-announces-issuance-composition-matter-patent-related-lenabasum\" target=\"_blank\">issuance </a>of a new U.S. composition of matter patent covering the use of lenabasum in a range of inflammatory and fibrotic diseases.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417859\" data-linked=\"Corbus Pharma up 3% premarket on new lenabasum patent\" data-tweet=\"$CRBP - Corbus Pharma up 3% premarket on new lenabasum patent https://seekingalpha.com/news/3417859-corbus-pharma-up-3-premarket-on-new-lenabasum-patent?source=tweet\" data-url=\"https://seekingalpha.com/news/3417859-corbus-pharma-up-3-premarket-on-new-lenabasum-patent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417857\" data-ts=\"1545142684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEET\" target=\"_blank\">MEET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417857-meet-groupplus-2_4-on-battles-rollout-nov-vid-rev\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meet Group +2.4% on Battles rollout, Nov. vid rev</a></h4><ul><li>The Meet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a>) <a href=\"https://seekingalpha.com/pr/17360910-meet-group-begins-rollout-battles-provides-update-progress\" target=\"_blank\">begins the rollout</a> for its Battles features on the MeetMe and Skout apps.</li><li>CEO Geoff Cook says video revenue run-rate exceeded $62M annualized in November, up from $55 million in October.</li><li>Meet Group shares are<font color=\"green\"> </font><font color=\"green\">up 2.4%</font> premarket to $3.45.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417857\" data-linked=\"Meet Group +2.4% on Battles rollout, Nov. vid rev\" data-tweet=\"$MEET - Meet Group +2.4% on Battles rollout, Nov. vid rev https://seekingalpha.com/news/3417857-meet-groupplus-2_4-on-battles-rollout-nov-vid-rev?source=tweet\" data-url=\"https://seekingalpha.com/news/3417857-meet-groupplus-2_4-on-battles-rollout-nov-vid-rev\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417855\" data-ts=\"1545142568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMRD\" target=\"_blank\">NMRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417855-nemaura-medical-prices-2_5m-stock-offering-shares-down-42-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nemaura Medical prices $2.5M stock offering; shares down 42% premarket</a></h4><ul> <li>Nemaura Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/NMRD' title='Nemaura Medical, Inc.'>NMRD</a>) <a href=\"https://seekingalpha.com/pr/17361213-nemaura-medical-announces-pricing-2_5-million-public-offering\" target=\"_blank\">prices</a> its public offering of  Company's common shares and warrants for expected gross proceeds of up to $2.5M.</li>   <li>The offering was priced at $1.04 per share, with each share coupled with one five-year warrant to purchase one share of common stock, at an exercise price of $1.04 per share.</li>    <li>Net proceeds will be used for a U.S. FDA clinical trial, product launch in Europe and the development of sugarBEAT, as well as for general corporate and working capital purposes.</li><li>Closing date is December 20.</li><li>Shares are down <font color=\"red\">42%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3417855\" data-linked=\"Nemaura Medical prices $2.5M stock offering; shares down 42% premarket\" data-tweet=\"$NMRD - Nemaura Medical prices $2.5M stock offering; shares down 42% premarket https://seekingalpha.com/news/3417855-nemaura-medical-prices-2_5m-stock-offering-shares-down-42-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3417855-nemaura-medical-prices-2_5m-stock-offering-shares-down-42-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417854\" data-ts=\"1545142406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRIN\" target=\"_blank\">MRIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417854-riot-mrin-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RIOT, MRIN among premarket gainers</a></h4><ul><li>Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a>) <font color=\"green\">+51%</font> on Google revenue sharing <a href=\"https://seekingalpha.com/news/3417735-marin-software-plus-50-percent-google-revenue-sharing-deal-updated-guidance\" target=\"_blank\">deal</a>, updated guidance.</li><li>Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) <font color=\"green\">+9%</font> on Sandoz <a href=\"https://seekingalpha.com/news/3417834-tilray-13-percent-premarket-sandoz-partnership\" target=\"_blank\">partnership</a>.</li><li>Achillion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3417666-achillion-2-percent-hours-positive-achminus-4471-data\" target=\"_blank\">positive</a> ACH-4471 data.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+8%</font>.</li><li>Uxin (NASDAQ:<a href='https://seekingalpha.com/symbol/UXIN' title='Uxin'>UXIN</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417854\" data-linked=\"RIOT, MRIN among premarket gainers\" data-tweet=\"$MRIN $MRIN $TLRY - RIOT, MRIN among premarket gainers https://seekingalpha.com/news/3417854-riot-mrin-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417854-riot-mrin-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417851\" data-ts=\"1545142237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMRD\" target=\"_blank\">NMRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417851-rcii-and-itci-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RCII and ITCI among premarket losers</a></h4><ul><li>Nemaura Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/NMRD' title='Nemaura Medical, Inc.'>NMRD</a>) <font color=\"red\">-40%</font> on <a href=\"https://seekingalpha.com/pr/17361213-nemaura-medical-announces-pricing-2_5-million-public-offering\" target=\"_blank\">pricing</a> $2.5M stock offering.</li><li>Rent-A-Center (NASDAQ:<a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a>) <font color=\"red\">-16%</font> after <a href=\"https://seekingalpha.com/news/3417782-rent-center-pulls-merger\" target=\"_blank\">terminating</a> its merger agreement with Vintage Capital.</li><li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a>) <font color=\"red\">-14%</font> on <a href=\"https://seekingalpha.com/pr/17361159-intra-cellular-therapies-announces-update-itiminus-007minus-201-clinical-trial-treatment\" target=\"_blank\">announcing</a> update on ITI-007-201 clinical trial for the treatment of agitation in patients with probable Alzheimer's disease.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417851\" data-linked=\"RCII and ITCI among premarket losers\" data-tweet=\"$NMRD $NMRD $RCII - RCII and ITCI among premarket losers https://seekingalpha.com/news/3417851-rcii-and-itci-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3417851-rcii-and-itci-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417849\" data-ts=\"1545142108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417849-tesla-takes-from-morgan-stanley-goldman-sachs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla takes from Morgan Stanley, Goldman Sachs</a></h4><ul> <li>Morgan Stanley sees the rally in Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) running out of steam shortly.</li> <li>\"While we acknowledge the significance of Tesla\u2019s very strong 3Q result, we do not believe investors will assume the company is fully self-sufficient without a more sustained period of execution,\" writes analyst Adam Jonas.</li> <li>Jonas <a href=\"https://www.bloomberg.com/news/articles/2018-12-18/tesla-shares-may-be-at-emerging-peak-morgan-stanley-says\" target=\"_blank\">points</a> to the ongoing concerns with Tesla's business in China and the European Union, while warning on an \"emerging peak\" in investor sentiment.</li> <li>Also weighing today on Tesla is the Goldman Sachs team, reiterating the firm's Sell rating and pointing once again to the new EV competition that Tesla faces.</li> <li>Shares of Tesla are <font color=\"green\">up 0.84%</font> in premarket action to $351.35 and are up 12% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417849\" data-linked=\"Tesla takes from Morgan Stanley, Goldman Sachs\" data-tweet=\"$TSLA - Tesla takes from Morgan Stanley, Goldman Sachs https://seekingalpha.com/news/3417849-tesla-takes-from-morgan-stanley-goldman-sachs?source=tweet\" data-url=\"https://seekingalpha.com/news/3417849-tesla-takes-from-morgan-stanley-goldman-sachs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>122&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417834\" data-ts=\"1545140514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417834-tilray-up-13-premarket-on-sandoz-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray up 13% premarket on Sandoz partnership</a></h4><ul><li>Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) is up <font color=\"green\">13%</font> premarket on light volume in reaction to its <a href=\"https://seekingalpha.com/pr/17361141-tilray-signs-global-collaboration-agreement-leading-pharmaceutical-company\" target=\"_blank\">announced collaboration</a> with Novartis' (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) Sandoz unit to globally commercialize Tilray's non-smokable/non-combustible medical cannabis products. Financial terms are not disclosed.</li><li><strong>Update</strong>: The companies have been <a href=\"https://www.bloomberg.com/news/articles/2018-12-18/tilray-goes-global-with-novartis-marijuana-sales-partnership?utm_medium=social&amp;cmpid=socialflow-twitter-business&amp;utm_source=twitter&amp;utm_content=business&amp;utm_campaign=socialflow-organic\" target=\"_blank\">working together</a> in Canada since March. They have co-branded eight oil and capsule medical cannabis products there and are joint members of the Common Initiative, a group promoting the distribution of medical cannabis in pharmacies, not currently allowed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417834\" data-linked=\"Tilray up 13% premarket on Sandoz partnership\" data-tweet=\"$TLRY $TLRY $NVS - Tilray up 13% premarket on Sandoz partnership https://seekingalpha.com/news/3417834-tilray-up-13-premarket-on-sandoz-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3417834-tilray-up-13-premarket-on-sandoz-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417828\" data-ts=\"1545139977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSPR\" target=\"_blank\">NSPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417828-inspiremd-up-11-premarket-on-new-data-supporting-cguard-eps\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InspireMD up 11% premarket on new data supporting CGuard EPS</a></h4><ul><li>Nano cap InspireMD (NYSEMKT:<a href='https://seekingalpha.com/symbol/NSPR' title='InspireMD, Inc.'>NSPR</a>) is up <font color=\"green\">11%</font> premarket on light volume on the heels of new <a href=\"https://seekingalpha.com/pr/17360984-inspiremd-announces-publication-meta-analysis-citing-benefits-next-generation-mesh-covered\" target=\"_blank\">metadata </a>supporting the value proposition of its MicroNet-covered CGuard Embolic Prevention System &#40;EPS&#41;.</li><li>Results from an analysis four clinical trials involving dual-layered and mesh-covered stents showed that carotid artery disease &#40;CAD&#41; patients who received mesh-covered stents experienced a 30-day minor stroke rate of 1.25%, lower than two widely cited studies in patients treated with both carotid endarterectomy (surgical plaque removal) and conventional carotid stents. In addition, the four studies involved a higher proportion of high-risk and elderly patients.</li><li>CEO James Barry, Ph.D. says, \u201cThe compelling results of this independent and comprehensive meta-analysis, which includes four studies of high-risk patients treated for carotid artery disease, add to the growing body of evidence that points to superior clinical outcomes with next generation mesh-covered or dual layered devices versus their conventional carotid stent counterparts. As we continue to expand the commercial availability of our MicroNet\u2122-covered product, CGuard\u2122 EPS, including the submission of a U.S. IDE expected in mid-2019, we welcome additional analyses such as these that further support the positive findings from our own studies with MicroNet-covered products.\u201d</li></ul><div class=\"tiny-share-widget\" data-id=\"3417828\" data-linked=\"InspireMD up 11% premarket on new data supporting CGuard EPS\" data-tweet=\"$NSPR - InspireMD up 11% premarket on new data supporting CGuard EPS https://seekingalpha.com/news/3417828-inspiremd-up-11-premarket-on-new-data-supporting-cguard-eps?source=tweet\" data-url=\"https://seekingalpha.com/news/3417828-inspiremd-up-11-premarket-on-new-data-supporting-cguard-eps\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417825\" data-ts=\"1545139829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417825-biocept-and-prognos-teams-up-to-apply-artificial-intelligence-for-commercialization-of\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept and Prognos teams up to apply artificial intelligence for commercialization of biomarker-targeted therapies in oncology</a></h4><ul><li>Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) has <a href=\"https://seekingalpha.com/pr/17361080-biocept-prognos-enter-partnership-apply-artificial-intelligence-order-help-pharmaceutical\" target=\"_blank\">entered</a> into a Software License and Laboratory Data Supply Agreement with Prognos, Inc.</li><li>Under the agreement, Biocept will supply de-identified data from its liquid biopsy testing to Prognos, to help its clients ensure that the right patients receive the right therapies.</li><li>Biocept will utilize Prognos' Opal de-identification software to collect and transmit the data to Prognos.</li>                  <li>Financial terms are not disclosed.</li><li>BIOC shares are up <font color=\"green\">31%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417825\" data-linked=\"Biocept and Prognos teams up to apply artificial intelligence for commercialization of biomarker-targeted therapies in oncology\" data-tweet=\"$BIOC - Biocept and Prognos teams up to apply artificial intelligence for commercialization of biomarker-targeted therapies in oncology https://seekingalpha.com/news/3417825-biocept-and-prognos-teams-up-to-apply-artificial-intelligence-for-commercialization-of?source=tweet\" data-url=\"https://seekingalpha.com/news/3417825-biocept-and-prognos-teams-up-to-apply-artificial-intelligence-for-commercialization-of\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417822\" data-ts=\"1545139583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHOP\" target=\"_blank\">SHOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417822-shopifyplus-2_8-on-wells-fargo-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shopify +2.8% on Wells Fargo initiation</a></h4><ul><li>Wells Fargo starts Shopify (NYSE:<a href='https://seekingalpha.com/symbol/SHOP' title='Shopify'>SHOP</a>) at Outperform with a $175 price target.</li><li>Analyst Timothy Willi calls Shopify an \u201cattractive way to invest in both the strong secular growth of digital commerce\" and DTC strategy growth by traditional retailers.</li><li>The analyst thinks SHOP can grow revenue at a rate of 30%+ over the next two to three years while a \"clear path to profitability\" emerges.</li><li>Source: Bloomberg First Word.</li><li>SHOP is <font color=\"green\">up 2.8%</font> premarket to $133.25.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417822\" data-linked=\"Shopify +2.8% on Wells Fargo initiation\" data-tweet=\"$SHOP - Shopify +2.8% on Wells Fargo initiation https://seekingalpha.com/news/3417822-shopifyplus-2_8-on-wells-fargo-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3417822-shopifyplus-2_8-on-wells-fargo-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417808\" data-ts=\"1545138322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417808-credit-suisse-sees-18-upside-in-abbott-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse sees 18% upside in Abbott in premarket analyst action</a></h4><ul><li>Abbott (NYSE:<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a>) initiated with Outperform rating and $82 (18% upside) price target at Credit Suisse.</li><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) initiated with Buy rating and $105 (41% upside) price target at Guggenheim.</li><li>Baxter International (NYSE:<a href='https://seekingalpha.com/symbol/BAX' title='Baxter International Inc'>BAX</a>) initiated with Outperform rating and $77 (20% upside) price target at Credit Suisse.</li><li>BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>) initiated with Neutral rating at Guggenheim.</li><li>Boston Scientific (NYSE:<a href='https://seekingalpha.com/symbol/BSX' title='Boston Scientific Corporation'>BSX</a>) initiated with Outperform rating and $42 (24% upside) price target at Credit Suisse.</li><li>Edwards Lifesciences (NYSE:<a href='https://seekingalpha.com/symbol/EW' title='Edwards Lifesciences Corp'>EW</a>) initiated with Outperform rating and $188 (21% upside) price target at Credit Suisse.</li><li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) initiated with Buy rating and $18 (72% upside) price target at Guggenheim.</li><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) resumed with Buy rating and $86 (32% upside) price target at Guggenheim.</li><li>Globus Medical (NYSE:<a href='https://seekingalpha.com/symbol/GMED' title='Globus Medical'>GMED</a>) initiated with Outperform rating and $53 (20% upside) price target at Credit Suisse.</li><li>Medtronic (NYSE:<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) initiated with Outperform rating and $109 (18% upside) price target at Credit Suisse.</li><li>NuVasive (NASDAQ:<a href='https://seekingalpha.com/symbol/NUVA' title='NuVasive, Inc.'>NUVA</a>) initiated with Outperform rating and $66 (24% upside) price target at Credit Suisse.</li><li>Integra LifeSciences Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/IART' title='Integra LifeSciences Holdings Corporation'>IART</a>) initiated with Outperform rating and $57 (21% upside) price target at Credit Suisse.</li><li>UniQure (NASDAQ:<a href='https://seekingalpha.com/symbol/QURE' title='uniQure N.V.'>QURE</a>) initiated with Buy rating and $35 (30% upside) price target at Guggenheim.</li><li>Stryker (NYSE:<a href='https://seekingalpha.com/symbol/SYK' title='Stryker Corporation'>SYK</a>) initiated with Outperform rating and $195 (22% upside) price target at Credit Suisse.</li><li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) resumed with Neutral rating at Guggenheim.</li><li>Wright Medical Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WMGI' title='Wright Medical Group, Inc.'>WMGI</a>) initiated with Outperform rating and $33 (24% upside) price target at Credit Suisse.</li><li>Zimmer Biomet Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ZBH' title='Zimmer Biomet Holdings, Inc.'>ZBH</a>) initiated with Underperform rating and $102 (5% downside risk) price target at Credit Suisse.</li><li>GlycoMimetics (NASDAQ:<a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a>) initiated with Buy rating and $24 (134% upside) price target at H.C. Wainwright.</li><li>CVS Health (NYSE:<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a>) initiated with Overweight rating and $91 (30% upside) at Barclays.</li><li>HealthEquity (NASDAQ:<a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a>) upgraded to Overweight with an $82 (38% upside) price target at Cantor Fitzgerald.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417808\" data-linked=\"Credit Suisse sees 18% upside in Abbott in premarket analyst action\" data-tweet=\"$ABT $ABT $ALNY - Credit Suisse sees 18% upside in Abbott in premarket analyst action https://seekingalpha.com/news/3417808-credit-suisse-sees-18-upside-in-abbott-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3417808-credit-suisse-sees-18-upside-in-abbott-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417795\" data-ts=\"1545136748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXRX\" target=\"_blank\">LXRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417795-lexicon-pharma-up-5-premarket-on-positive-lx9211-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lexicon Pharma up 5% premarket on positive LX9211 data</a></h4><ul><li>Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) is up <font color=\"green\">5%</font> premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17360875-lexicon-pharmaceuticals-announces-positive-topline-clinical-data-lx9211\" target=\"_blank\">announcement </a>of positive results from a Phase 1a clinical trial evaluating neuropathic pain candidate LX9211.</li><li>The study met its primary objectives, demonstrating a favorable safety and tolerability profile and identifying the maximum tolerated dose.</li><li>The most common adverse event was headache.</li><li>A multiple ascending-dose study should launch next quarter.</li><li>Small molecule LX9211 inhibits an enzyme called adaptor-associated protein kinase 1 (AAK1). The company acquired exclusive rights from development partner Bristol-Myers Squibb two years ago.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417795\" data-linked=\"Lexicon Pharma up 5% premarket on positive LX9211 data\" data-tweet=\"$LXRX - Lexicon Pharma up 5% premarket on positive LX9211 data https://seekingalpha.com/news/3417795-lexicon-pharma-up-5-premarket-on-positive-lx9211-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3417795-lexicon-pharma-up-5-premarket-on-positive-lx9211-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417788\" data-ts=\"1545136085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417788-oracle-provides-upside-q3-guidance-sharesplus-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle provides upside Q3 guidance; shares +5%</a></h4><ul><li>Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) provides Q3 guidance on the earnings call with EPS expected from $0.86 to $0.88 (consensus: $0.84).</li><li>Currency could be as much as a 4% headwind on total revenue with a -$0.03 impact on EPS. Total revenue (constant currency) is guided up 2% to 4% Y/Y (consensus: +0.7% Y/Y).</li><li>FY19 guidance expects revenue acceleration in the second half of the year.</li><li>Earnings call transcript is available <a href=\"https://seekingalpha.com/article/4228843-oracle-corporation-orcl-ceo-safra-catz-mark-hurd-q2-2019-results-earnings-call-transcript\" target=\"_blank\">here</a>.</li><li>Oracle shares are <font color=\"green\">up 5%</font> premarket to $48.02.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417667-oracle-plus-3_5-percent-q2-beats\" target=\"_blank\">Oracle +3.5% on Q2 beats</a> (Dec. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3417788\" data-linked=\"Oracle provides upside Q3 guidance; shares +5%\" data-tweet=\"$ORCL - Oracle provides upside Q3 guidance; shares +5% https://seekingalpha.com/news/3417788-oracle-provides-upside-q3-guidance-sharesplus-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3417788-oracle-provides-upside-q3-guidance-sharesplus-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417781\" data-ts=\"1545135461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417781-rbc-positive-on-amd-joining-nasdaq-100\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC positive on AMD joining Nasdaq 100</a></h4><ul><li>RBC Capital Markets analyst Mitch Steves sees \"a small near-term positive impact\" for AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) from joining the Nasdaq 100.</li><li>Steves says the \"small news item\" is \"important from a trading perspective.\"</li><li>Steves reiterates an Outperform rating and $34 price target.</li><li>Source: Bloomberg First Word.</li><li>AMD, NetApp (NASDAQ:<a href='https://seekingalpha.com/symbol/NTAP' title='NetApp, Inc.'>NTAP</a>), and VeriSign (NASDAQ:<a href='https://seekingalpha.com/symbol/VRSN' title='VeriSign, Inc.'>VRSN</a>) are among the six companies <a href=\"https://www.nasdaq.com/press-release/annual-changes-to-the-nasdaq100-index-20181214-00735\" target=\"_blank\">joining the index</a> with its annual re-ranking, effective prior to market open on December 24.</li><li>AMD shares are <font color=\"green\">up 1.2%</font> premarket to $19.06.</li></ul><div class=\"tiny-share-widget\" data-id=\"3417781\" data-linked=\"RBC positive on AMD joining Nasdaq 100\" data-tweet=\"$AMD $AMD $NTAP - RBC positive on AMD joining Nasdaq 100 https://seekingalpha.com/news/3417781-rbc-positive-on-amd-joining-nasdaq-100?source=tweet\" data-url=\"https://seekingalpha.com/news/3417781-rbc-positive-on-amd-joining-nasdaq-100\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3417775\" data-ts=\"1545135081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRI\" target=\"_blank\">DRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3417775-darden-lifts-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Darden lifts profit guidance</a></h4><ul> <li>Darden Restaurants (NYSE:<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a>) edges EPS estimates with its <a href=\"https://seekingalpha.com/pr/17360829-darden-restaurants-reports-fiscal-2019-second-quarter-results-increases-financial-outlook\" target=\"_blank\">FQ2</a> earnings report on total sales growth of 4.9%.</li> <li>Darden reports comparable sales were up 3.5% during the quarter, off a 1.9% gain in pricing and 2.4% positive contribution from menu-mix. Same-restaurant traffic was down 0.8%.</li> <li>Comparable sales by chain: Olive Garden +3.5% vs. +3.4% consensus, LongHorn +2.9%, +3.7% Capital Grille, +0.9% Eddie V's, -4.0% Cheddar Scratch Kitchen, -1.1% Yard House, -0.8% Seasons 52, -1.1% Bahama Breeze.</li> <li>Looking ahead, Darden expects same-restaurant sales growth of 2.5% in FY19 and EPS of $5.60 to $5.70 vs. $5.52 to $5.65 prior and $5.65 consensus.</li> <li>DRI <font color=\"green\">+0.15%</font> premarket to $98.91</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417769-darden-restaurants-beats-0_01-misses-revenue\" target=\"_blank\">Darden Restaurants beats by $0.01, misses on revenue</a> (Dec. 18)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3417775\" data-linked=\"Darden lifts profit guidance\" data-tweet=\"$DRI - Darden lifts profit guidance https://seekingalpha.com/news/3417775-darden-lifts-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3417775-darden-lifts-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":56,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}